CMS Coverage With Evidence Development-Challenges and Opportunities for Improvement.
作者信息
Phillips Kathryn A
机构信息
UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), Department of Clinical Pharmacy, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
出版信息
JAMA Health Forum. 2022 Sep 2;3(9):e223061. doi: 10.1001/jamahealthforum.2022.3061.
Abstract
摘要
相似文献
1
CMS Coverage With Evidence Development-Challenges and Opportunities for Improvement.医疗保险与证据发展覆盖范围——改进的挑战与机遇
JAMA Health Forum. 2022 Sep 2;3(9):e223061. doi: 10.1001/jamahealthforum.2022.3061.
2
SNMMI Reacts to CMS Coverage Decision.核医学与分子影像学会对医疗保险与医疗补助服务中心的覆盖范围决定作出回应。
J Nucl Med. 2022 Mar;63(3):12N.
3
Statutory Authority for Medicare Coverage Decisions-CMS Is an Independent Federal Agency.医疗保险覆盖范围决策的法定授权——医疗保险和医疗补助服务中心是一个独立的联邦机构。
JAMA Intern Med. 2023 Sep 1;183(9):910-912. doi: 10.1001/jamainternmed.2023.4082.
4
5
Centers for Medicare and Medicaid Services Coverage of Amyloid PET.医疗保险和医疗补助服务中心对淀粉样蛋白PET的覆盖范围。
JAMA Neurol. 2024 Sep 1;81(9):903-904. doi: 10.1001/jamaneurol.2024.2100.
6
Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?美国医疗保险和医疗补助服务中心（CMS）会在阿杜卡努单抗获得美国食品药品监督管理局（FDA）批准后，认定其对阿尔茨海默病的治疗合理且必要吗？
JAMA. 2021 Aug 3;326(5):383-384. doi: 10.1001/jama.2021.11768.
7
Medicare 101: Navigating the Rules for Coverage and Benefits in Clinical Practice.医疗保险基础：临床实践中解读保险范围及福利规则
Fam Pract Manag. 2022 Jan-Feb;29(1):21-25.
8
Data Characterization of Medicaid: Legacy and New Data Formats in the CMS Virtual Research Data Center.医疗补助数据特征：CMS 虚拟研究数据中心中的传统和新数据格式。
AMIA Jt Summits Transl Sci Proc. 2021 May 17;2021:644-652. eCollection 2021.
9
Bariatric surgery complications before vs after implementation of a national policy restricting coverage to centers of excellence.减重手术并发症在国家政策实施前后对比，该政策限制了覆盖范围至卓越中心。
JAMA. 2013 Feb 27;309(8):792-9. doi: 10.1001/jama.2013.755.
10
Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.2005年至2016年支持美国食品药品监督管理局（FDA）批准和医疗保险与医疗补助服务中心（CMS）对新型医疗产品进行全国医保覆盖范围认定的证据：一项横断面研究。
Medicine (Baltimore). 2018 Oct;97(40):e12715. doi: 10.1097/MD.0000000000012715.
引用本文的文献
1
Clinically meaningful benefit and real-world evidence in Alzheimer's disease research and care.阿尔茨海默病研究与照护中的临床意义上的益处及真实世界证据。
Alzheimers Dement (N Y). 2025 Apr 24;11(2):e70090. doi: 10.1002/trc2.70090. eCollection 2025 Apr-Jun.
2
Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.意大利药品管理准入协议的财务结果。
JAMA Health Forum. 2023 Dec 1;4(12):e234611. doi: 10.1001/jamahealthforum.2023.4611.
3
Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.改进食品药品监督管理局与医疗保险和医疗补助服务中心对加速批准药物的协调。
Milbank Q. 2023 Dec;101(4):1047-1075. doi: 10.1111/1468-0009.12670. Epub 2023 Aug 29.
4
Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests.展望未来：等待多癌早期检测测试结果时对初级保健的影响。
Healthc (Amst). 2023 Sep;11(3):100705. doi: 10.1016/j.hjdsi.2023.100705. Epub 2023 Aug 18.
本文引用的文献
1
Coverage with evidence development: where are we now?循证医保覆盖：现状如何？
Am J Manag Care. 2022 Aug;28(8):382-389. doi: 10.37765/ajmc.2022.88870.
2
Coverage with evidence development for medical devices in Europe: Can practice meet theory?医疗器械的证据开发覆盖范围在欧洲：实践能否符合理论？
Health Econ. 2022 Sep;31 Suppl 1(Suppl 1):179-194. doi: 10.1002/hec.4478. Epub 2022 Feb 26.
3
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.医疗器械的证据开发计划的覆盖范围在欧洲：特点和挑战。
Eur J Health Econ. 2021 Nov;22(8):1253-1273. doi: 10.1007/s10198-021-01334-9. Epub 2021 Jun 12.
4
Performance-Based Risk-Sharing Arrangements: An Updated International Review.基于绩效的风险分担安排：最新国际综述。
Pharmacoeconomics. 2017 Oct;35(10):1063-1072. doi: 10.1007/s40273-017-0535-z.
5
Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.基于绩效的风险分担安排——设计、实施和评估的良好实践：ISPOR 基于绩效的风险分担安排良好实践工作组的报告。
Value Health. 2013 Jul-Aug;16(5):703-19. doi: 10.1016/j.jval.2013.04.011. Epub 2013 Jul 19.
Zotero 插件